A responsive scientist with an important new pathological finding does not start treating patients with anticoagulant cocktails outside trials and sending them to Germany for some special sort of apheresis. Germany seems to be a place where questionable haematological procedures are allowed. Why isn't this being done in S Africa if it is a well recognised procedure? Why not the USA or the UK?
Agree with your disquiet - much of this scenario is less than ideal, best practice or the way we would wish things.
However, for your point 4 I don't
think that's what happened. I believe the patients were taking themselves to Germany, possibly because word of mouth suggested that this technique was found to be helping Long COVID patients.
The LC community have been very active in sharing information online, so this info would spread quickly. Like us they've struggled to be believed, been forced to self-advocate and, with no offered treatments beyond BPS, have been sharing ideas on what they thought helped them. Their community has formed rapidly and with big numbers in an era of easy transmission of information (valid and invalid).
As I understand it, the South African team have been invited to analyse the blood before and after treatment to see if there are micro-clots present and whether they reduce. Nothing more than that, I believe. Prof Pretorius has indicated plans for a blood study of her regional ME patients starting in 3 months, so no rush there.
This may have been serendipitous. Eg a patient that was having routine treatment for, say, severe familial dyslipidaemia happened to get long COVID and may have reported improvement in their LC symptoms following scheduled treatments. Similar to what kicked off the rituximab trial I believe.
I think HELP apheresis is not commonly used outside of a few countries. Entirely possible it's not available in the US and UK at all.
I completely agree, first order of the day is to see if the micro-clot finding is real / repeatable and what its specificity is. Then work out how it might induce symptoms. Then start evaluating treatments with properly designed trials.
At the moment a lot of this remains opaque. If I'm presented with an opportunity to communicate directly with the relevant parties, I will share anything appropriate for an open forum.